SEC Form 4 · accession 0001493152-26-043443
Vivos Therapeutics, Inc. · VVOS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leonard J Sokolow
Director
Period of report
Sep 14, 2026
Accepted (ET)
Sep 18, 2026 · 8:20 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001716166
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $0.18 | Sep 14, 2026 | A | 12,000 | A | Sep 14, 2026 | Sep 14, 2036 | Common Stock | 12,000 | 17,600 | D |
Explanation of responses
- F1On September 14, 2026 (the "Grant Date"), the Reporting Person received a grant of 12,000 stock options from the Issuer. One-half vested immediately (and the earliest possible exercise date in Table II relates to this tranche), one-fourth will vest on September 30, 2026 and one-fourth will vest on December 31, 2026. The options are exercisable for a period of 10 years from the Grant Date. Reflects expiry of 667 options on June 19, 2025 and 1,200 options on August 5, 2026, all of which expired unexercised.